FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Françoise Révillion

Research Profile

Disorders

Chemicals & Drugs

Procedures

Reverse Transcriptase Polymerase Chain Reaction

Physiology

Anatomy

Concepts & Ideas

Survival Analysis

Co-author Network

Publications

TOP 3
J Bonneterre; C Desauw; C Fournier; Louis Hornez; A Kramar; E Blot; Françoise Révillion; J P Peyrat
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Pascaline Gaildrat; Agnès Hardouin; Claude Houdayer; Estelle Jamard; Sophie Krieger; Danielle Ledemeney; Rosette Lidereau; Julie Abdat; Elodie BOHERS; Sandrine Caputo; Daniela Di Giacomo; Thierry Frébourg; Jean-Philippe Peyrat; Françoise Révillion; Etienne Rouleau; Mario Tosi; Dominique Vaur; Alexandra Martins
Multiple sequence variants of BRCA2 exon 7 alter splicing regulation.
Claude Houdayer; Sophie Krieger; Cédrick Lefol; Mélanie Léone; Rosette Lidereau; Sylvie Mazoyer; Danielle Muller; Audrey Remenieras; Françoise Révillion; Etienne Rouleau; Nicolas Sevenet; Olga M Sinilnikova; Hagay Sobol; Joanna Sokolowska; Florent Soubrier; Michel BARROIS; Françoise Bonnet; Violaine Bourdon; Brigitte Bressac De-Paillerets; Myriam Bronner; Monique Buisson; Virginie Caux-Moncoutier; Florence Coulet; Pascaline Gaildrat; Agnès Hardouin; Mario Tosi; Jean-Philippe Vert; Dominique Stoppa-Lyonnet
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Françoise Révillion (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: J Bonneterre; C Desauw; C Fournier; Louis Hornez; A Kramar; E Blot; Françoise Révillion; J P Peyrat
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Oncology reports 2013;29(1):355-61.
2012: Pascaline Gaildrat; Agnès Hardouin; Claude Houdayer; Estelle Jamard; Sophie Krieger; Danielle Ledemeney; Rosette Lidereau; Julie Abdat; Elodie BOHERS; Sandrine Caputo; Daniela Di Giacomo; Thierry Frébourg; Jean-Philippe Peyrat; Françoise Révillion; Etienne Rouleau; Mario Tosi; Dominique Vaur; Alexandra Martins
Multiple sequence variants of BRCA2 exon 7 alter splicing regulation.
Journal of medical genetics 2012;49(10):609-17.
2012: Claude Houdayer; Sophie Krieger; Cédrick Lefol; Mélanie Léone; Rosette Lidereau; Sylvie Mazoyer; Danielle Muller; Audrey Remenieras; Françoise Révillion; Etienne Rouleau; Nicolas Sevenet; Olga M Sinilnikova; Hagay Sobol; Joanna Sokolowska; Florent Soubrier; Michel BARROIS; Françoise Bonnet; Violaine Bourdon; Brigitte Bressac De-Paillerets; Myriam Bronner; Monique Buisson; Virginie Caux-Moncoutier; Florence Coulet; Pascaline Gaildrat; Agnès Hardouin; Mario Tosi; Jean-Philippe Vert; Dominique Stoppa-Lyonnet
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.
Human mutation 2012;33(8):1228-38.
2012: Clothilde Lindet; Jean-Philippe Peyrat; Françoise Révillion; Louis Hornez; Valérie Lhotellier; Jacques Bonneterre
Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.
The International journal of biological markers 2012;27(2):e111-7.
2011: Jean Christophe Théry; Dominique Vaur; Pascaline Berthet; Marie-Pierre Buisine; Christiane Duponchel; Thierry Frébourg; Pascaline Gaildrat; Agnès Hardouin; Audrey Killian; Sophie Krieger; Alexandra Martins; Jean-Philippe Peyrat; Françoise Révillion; Antoine Rousselin; Mario Tosi
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
European journal of human genetics : EJHG 2011;19(10):1052-8.
2009: Mohamed Hebbar; Antoine Adenis; Françoise Révillion; Alain Duhamel; Olivier Romano; Stéphanie Truant; Christian Libersa; Claire Giraud; Jean-Pierre Triboulet; François-René Pruvot; Jean-Philippe Peyrat
E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2009;45(10):1871-6.
2009: Françoise Révillion; Carole Puech; Fanja Rabenoelina; Dany Chalbos; Jean-Philippe Peyrat; Gilles Freiss
Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer.
International journal of cancer. Journal international du cancer 2009;124(3):638-43.
2008: Françoise Révillion; Valérie Lhotellier; Louis Hornez; A Leroy; M C Baranzelli; Sylvia Giard; Jacques Bonneterre; Jean-Philippe Peyrat
Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.
The International journal of biological markers 2008;23(1):10-7.
2008: Françoise Révillion; Valérie Lhotellier; Louis Hornez; Jacques Bonneterre; Jean-Philippe Peyrat
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(1):73-80.
2007: Michael C Haffner; Barbara Petridou; Jean-Philippe Peyrat; Françoise Révillion; Elisabeth Müller-Holzner; Guenter Daxenbichler; Christian Marth; Wolfgang Doppler
Favorable prognostic value of SOCS2 and IGF-I in breast cancer.
BMC cancer 2007;7():136.
2006: Florence Gizard; Romain Robillard; Barbara Gross; Olivier Barbier; Françoise Révillion; Jean-Philippe Peyrat; Gérard Torpier; Dean W Hum; Bart Staels
TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.
Molecular and cellular biology 2006;26(20):7632-44.
2006: Françoise Révillion; Madia Charlier; Valérie Lhotellier; Louis Hornez; Sylvia Giard; Marie-Christine Baranzelli; Jean Djiane; Jean-Philippe Peyrat
Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2088-94.
2005: Florence Gizard; Romain Robillard; Philippe Gervois; Anne Faucompré; Françoise Révillion; Jean-Philippe Peyrat; W Dean Hum; Bart Staels
Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene.
FEBS letters 2005;579(25):5535-41.
2005: Florence Gizard; Romain Robillard; Olivier Barbier; Brigitte Quatannens; Anne Faucompré; Françoise Révillion; Jean-Philippe Peyrat; Bart Staels; Dean W Hum
TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.
Molecular and cellular biology 2005;25(11):4335-48.
2004: Anne Chotteau-Lelièvre; Françoise Révillion; Valérie Lhotellier; Louis Hornez; Xavier Desbiens; Véronique Cabaret; Yvan de Launoit; Jean-Philippe Peyrat
Prognostic value of ERM gene expression in human primary breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7297-303.
2004: Françoise Révillion; Alain Verdière; Joëlle Fournier; Louis Hornez; Jean-Philippe Peyrat
Multiplex single-nucleotide primer extension analysis to simultaneously detect eleven BRCA1 mutations in breast cancer families.
Clinical chemistry 2004;50(1):203-6.
2001: Hubert Hondermarck; Anne-Sophie Vercoutter-Edouart; Françoise Révillion; Jérôme Lemoine; Ikram El Yazidi-Belkoura; Victor Nurcombe; Jean-Philippe Peyrat
Proteomics of breast cancer for marker discovery and signal pathway profiling.
Proteomics 2001;1(10):1216-32.
2001: Simon Descamps; Valérie Pawlowski; Françoise Révillion; Louis Hornez; Mohamed Hebbar; Bénoni Boilly; Hubert Hondermarck; Jean-Philippe Peyrat
Expression of nerve growth factor receptors and their prognostic value in human breast cancer.
Cancer research 2001;61(11):4337-40.
2001: Anne-Sophie Vercoutter-Edouart; Jérôme Lemoine; Xuefen Le Bourhis; H Louis; Bénoni Boilly; Victor Nurcombe; Françoise Révillion; Jean-Philippe Peyrat; Hubert Hondermarck
Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells.
Cancer research 2001;61(1):76-80.
2000: Valérie Pawlowski; Françoise Révillion; Mohamed Hebbar; Louis Hornez; Jean-Philippe Peyrat
Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4217-25.
2000: Françoise Révillion; Valérie Pawlowski; Louis Hornez; Jean-Philippe Peyrat
Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer.
European journal of cancer (Oxford, England : 1990) 2000;36(8):1038-42.
2000: Valérie Pawlowski; Françoise Révillion; Louis Hornez; Jean-Philippe Peyrat
A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.
Cancer detection and prevention 2000;24(3):212-23.
1999: Mohamed Hebbar; Françoise Révillion; Marie-Michèle Louchez; Charles Fournier; Jacques Bonneterre; Jean-Philippe Peyrat
Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1427-33.
1999: Claude Preudhomme; Françoise Révillion; A Merlat; Louis Hornez; Christophe Roumier; N Duflos-Grardel; J P Jouet; Alain Cosson; Jean-Philippe Peyrat; Pierre Fenaux
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
Leukemia 1999;13(6):957-64.
1998: Françoise Révillion; Jacques Bonneterre; Jean-Philippe Peyrat
ERBB2 oncogene in human breast cancer and its clinical significance.
European journal of cancer (Oxford, England : 1990) 1998;34(6):791-808.
1998: Jean-Philippe Peyrat; Françoise Révillion; Jacques Bonneterre
Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
British journal of cancer 1998;77(10):1669-71.
1998: Mohamed Hebbar; Françoise Révillion; Marie-Michèle Louchez; Marie-Odile Vilain; Charles Fournier; Jacques Bonneterre; Jean-Philippe Peyrat
The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):373-80.
1998: Jean-Philippe Peyrat; L Vanlemmens; Joëlle Fournier; G Huet; Françoise Révillion; Jacques Bonneterre
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):189-96.
1997: Françoise Révillion; Louis Hornez; Jean-Philippe Peyrat
Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR.
Clinical chemistry 1997;43(11):2114-20.
1991: B Vandewalle; Louis Hornez; Françoise Révillion; J Lefebvre
Cyclic AMP stimulation of transferrin secretion by breast cancer cell grown on extracellular matrix or in two-compartment culture chambers.
Biochemical and biophysical research communications 1991;177(3):1041-8.